Tambotatug pelitecan is a novel antibody-drug conjugate that delivers a topoisomerase I inhibitor to (typically malignant) cells highly-expressing the immune checkpoint inhibitor B7-H3, and it successfully prolonged overall survival patients as second-line therapy for extensive‑stage SCLC in a Chinese phase 3 trial. | Zhao, N Engl J Med 2026
